Recce Ltd has released a press release.
Appendix 4E
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4e-233
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Phase I Clinical Trial of R327 I.V. - 6000mg Complete
- Corporate Presentation - Aussie Equities Day 2022
- Phase I Positive Safety Data - 4000mg Complete
- Phase I Clinical Trial R327 Advances to 4000mg
- Corporate Presentation - Biotech Investor Lunch
Later from Recce Pharmaceuticals
- Expansion and Acceleration of Clinical Programs
- R327 COVID Study Update
- Pause in trading
- Anti-Infective Portfolio Update and Webinar details
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals